Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Astria Therapeutics (ATXS) EBIT: 2017-2018

Historic EBIT for Astria Therapeutics (ATXS) over the last 2 years, with Dec 2018 value amounting to -$6.1 million.

  • Astria Therapeutics' EBIT fell 10.75% to -$6.1 million in Q4 2018 from the same period last year, while for Dec 2018 it was -$26.4 million, marking a year-over-year increase of 2.79%. This contributed to the annual value of -$26.4 million for FY2018, which is 2.67% up from last year.
  • As of Q4 2018, Astria Therapeutics' EBIT stood at -$6.1 million, which was down 1.33% from -$6.0 million recorded in Q3 2018.
  • Astria Therapeutics' 5-year EBIT high stood at -$5.5 million for Q4 2017, and its period low was -$7.8 million during Q1 2017.
  • Its 2-year average for EBIT is -$6.7 million, with a median of -$6.8 million in 2017.
  • Examining YoY changes over the last 5 years, Astria Therapeutics' EBIT showed a top increase of 13.58% in 2018 and a maximum decrease of 10.75% in 2018.
  • Astria Therapeutics' EBIT (Quarterly) stood at -$5.5 million in 2017, then dropped by 10.75% to -$6.1 million in 2018.
  • Its EBIT was -$6.1 million in Q4 2018, compared to -$6.0 million in Q3 2018 and -$6.6 million in Q2 2018.